T
Thomas A. Hope
Researcher at University of California, San Francisco
Publications - 255
Citations - 8966
Thomas A. Hope is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 40, co-authored 201 publications receiving 5914 citations. Previous affiliations of Thomas A. Hope include Veterans Health Administration & Society of Nuclear Medicine and Molecular Imaging.
Papers
More filters
Journal ArticleDOI
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
Wolfgang P. Fendler,Wolfgang P. Fendler,Matthias Eiber,Matthias Eiber,Mohsen Beheshti,Jamshed Bomanji,Francesco Ceci,Steven Cho,Frederik L. Giesel,Uwe Haberkorn,Thomas A. Hope,Klaus Kopka,Bernd J. Krause,Felix M. Mottaghy,Heiko Schöder,John Sunderland,Simon Wan,Hans-Juergen Wester,Stefano Fanti,Ken Herrmann +19 more
TL;DR: These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer imaging and are needed for implementation of this modality in science and routine clinical practice.
Journal ArticleDOI
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler,Wolfgang P. Fendler,Jeremie Calais,Matthias Eiber,Matthias Eiber,Robert R. Flavell,Ashley Mishoe,Felix Y. Feng,Hao G. Nguyen,Robert E. Reiter,Matthew Rettig,Shozo Okamoto,Louise Emmett,Helle D Zacho,Harun Ilhan,Axel Wetter,Christoph Rischpler,Heiko Schöder,Irene A. Burger,Jeannine Gartmann,Raven Smith,Eric J. Small,Roger Slavik,Peter R. Carroll,Ken Herrmann,Ken Herrmann,Johannes Czernin,Thomas A. Hope +27 more
TL;DR: Using blinded reads and independent lesion validation, this single-arm prospective trial establishes high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer.
Journal ArticleDOI
Bicuspid Aortic Valve: Four-dimensional MR Evaluation of Ascending Aortic Systolic Flow Patterns
Michael D. Hope,Thomas A. Hope,Alison K. Meadows,Karen G. Ordovas,Thomas H. Urbania,Marcus T. Alley,Charles B. Higgins +6 more
TL;DR: Four-dimensional flow MR imaging showed abnormal helical systolic flow in the ascending aorta of patients with a BAV, including those without aneurysm or aortic stenosis, and identification and characterization of eccentric flow jets in these patients may help identify those at risk for development of ascendingAortic aneurYSm.
Journal ArticleDOI
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber,Matthias Eiber,Ken Herrmann,Jeremie Calais,Boris Hadaschik,Frederik L. Giesel,Markus Hartenbach,Thomas A. Hope,Robert E. Reiter,Tobias Maurer,Wolfgang A. Weber,Wolfgang P. Fendler,Wolfgang P. Fendler +12 more
TL;DR: A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
Journal ArticleDOI
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Jeremie Calais,Francesco Ceci,Francesco Ceci,Matthias Eiber,Matthias Eiber,Thomas A. Hope,Michael S Hofman,Christoph Rischpler,Tore Bach-Gansmo,Cristina Nanni,Bital Savir-Baruch,David Elashoff,Tristan Grogan,Magnus Dahlbom,Roger Slavik,Jeannine Gartmann,Kathleen Nguyen,Vincent Lok,Hossein Jadvar,Amar U. Kishan,Matthew Rettig,Robert E. Reiter,Wolfgang P. Fendler,Wolfgang P. Fendler,Johannes Czernin +24 more
TL;DR: Comparing prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations found PSMA should be the PET tracer of choice when PET- CT imaging is considered for subsequent treatment management decisions.